Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 26;28(9):501.
doi: 10.1007/s00784-024-05898-7.

Botulinum toxin for bruxism treatment: a nationwide study among oral and maxillofacial surgeons in Germany

Andreas Pabst  1   2 , Peer W Kämmerer  3 , Diana Heimes  3 , Alexander-N Zeller #  4   5 , Matthias Quarta #  6
Affiliations

Botulinum toxin for bruxism treatment: a nationwide study among oral and maxillofacial surgeons in Germany

Andreas Pabst et al. Clin Oral Investig. .

Abstract

Introduction: This study aimed to evaluate the use of botulinum toxin (BTX) for the treatment of bruxism in oral and maxillofacial surgery in Germany.

Material and methods: A dynamic online questionnaire comprising 7 to 25 questions was formulated to gather general and specific information regarding using BTX to treat bruxism. The questionnaire underwent internal and external assessments for validation. Subsequently, it was distributed to 906 oral and maxillofacial surgeons (OMFS) affiliated with the German Association for Oral and Maxillofacial Surgery (DGMKG). Weekly reminders were dispatched over four weeks to enhance response rates. Participation in the study was voluntary and anonymized. Descriptive methods were employed for data analysis.

Results: 107 OMFS participated in the study, yielding a response rate of 11.81%. On average, 17 patients with bruxism were per month, with 4 of these patients receiving BTX therapy. BTX administration was frequently accompanied by splints and physiotherapy (35.51% of participants). Botox® (Allergan) was the preferred BTX preparation, utilized by 40.79% and reconstituted with saline by 92.11% of participants. The masseter muscles were primarily targeted for BTX treatment (67.57% of participants), averaging 29 BTX (Allergan-) units per side. Injection points for each masseter muscle typically amounted to six per side, preferred by 30.67% of participants. Follow-up assessments post-BTX treatment were conducted regularly, predominantly after four weeks, by 36% of participants. In 8% of cases, additional BTX injections were necessary due to inadequate outcomes. Side effects were reported in 4% of cases, commonly manifesting as a non-disturbing reduction in bite force. Most participating OMFS (61.84%) using BTX for bruxism therapy regarded bruxism treatment with BTX as evidence-based. Notably, 97.37% of respondents expressed their willingness to recommend BTX-based bruxism treatment to their colleagues. Overall, the efficacy of BTX therapy for bruxism was rated as good (53.95%) and very good (40.79%).

Conclusion: The use of BTX for the management of bruxism among OMFS in Germany has demonstrated efficacy. Substantial variances in certain facets of bruxism treatment employing BTX have been observed.

Clinical relevance: Additional research endeavors are warranted to comprehensively investigate distinct elements of BTX therapy for bruxism, including the optimal dosage of BTX units and the precise localization of injection sites across various muscles.

Keywords: BTX; Botulinum toxin; Bruxism; Oral and maxillofacial surgery; Survey.

PubMed Disclaimer

References

    1. Lobbezoo F, Ahlberg J, Glaros AG, Kato T, Koyano K, Lavigne GJ, de Leeuw R, Manfredini D, Svensson P, Winocur E (2013) Bruxism defined and graded: an international consensus. J Oral Rehabil 40(1):2–4. https://doi.org/10.1111/joor.12011 - PubMed
    1. Manfredini D, Ahlberg J, Lavigne GJ, Svensson P, Lobbezoo F (2023) Five years after the 2018 consensus definitions of sleep and awake bruxism: An explanatory note. J Oral Rehabil. https://doi.org/10.1111/joor.13626 - PubMed
    1. Lavigne GJ, Khoury S, Abe S, Yamaguchi T, Raphael K (2008) Bruxism physiology and pathology: an overview for clinicians. J Oral Rehabil 35(7):476–494. https://doi.org/10.1111/j.1365-2842.2008.01881.x - PubMed
    1. Rofaeel M, Chow JC, Cioffi I (2021) The intensity of awake bruxism episodes is increased in individuals with high trait anxiety. Clin Oral Investig 25(5):3197–3206. https://doi.org/10.1007/s00784-020-03650-5 - PubMed
    1. Archer AB, Da-Cas CD, Valesan LF, Cunha TCA, Januzzi E, Garanhani RR, de La Torre CG, de Souza BDM (2023) Prevalence of awake bruxism in the adult population: a systematic review and meta-analysis. Clin Oral Investig 27(12):7007–7018. https://doi.org/10.1007/s00784-023-05302-w - PubMed

Substances

LinkOut - more resources